Paediatric acute liver failure (P-ALF) is a rare disease with a significant fatality rate. The goal of P-ALF management is to stabilise essential organ functioning, eliminate circulating contaminants, and replace missing plasma components.The purpose of this research is to report on the safety and practicality of using HVP in P-ALF. P-ALF children were given HVP if the bilirubin exceeded 200 milligrammes per litre or if the aetiology was toxic hepatitis. HVP has been carried out on a minimum of 3 consecutive days with fresh frozen plasma that equates to 10% of the body weight. From 2012 to 2019, retrospectively analysed diagnoses, biochemical and clinical evidence during HVP and outcome data after 3 months were gathered.
16 children received HVP treatment and completed a minimum of one set of three HVP treatment sessions. The only issue seen in 3 children in the first 12 hours was an elevation in pH > 7.55 and HCl correction. During HVP there were no bleeding or septic episodes. After successful grafting 2 of the infants survived without liver transplantation and a total of 6 of them died. The liver injury unit score was considerably different between survivors who had their own liver and the remainder. HVP is feasible and well tolerated in children with P-ALF with fresh frozen plasma.
